GNS Pens Cancer Rx-Dx-Development Alliance With Moffitt Subsidiary M2Gen | GenomeWeb
NEW YORK (GenomeWeb News) — Gene Network Sciences said today that it will use its REFSTM software in an alliance with H. Lee Moffitt Cancer Center subsidiary M2Gen to develop cancer diagnostics and therapeutics
 
GNS will use REFSTM, which stands for reverse engineering and forward simulation, to reverse-engineer computer models from de-identified tumor molecular profiling data provided by Moffitt.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.